Suchergebnisse - "Widge, Alicia T"

PubPharm (17)

1

Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults : a phase 1, open-label, dose-escalation clinical trial

enthalten in: The Lancet. Infectious diseases | 2023

von Mwesigwa, B. | Houser, K. | Hofstetter, A. | +73

ErratumIn: Lancet Infect Dis. 2023 Oct;23(10):e400. - PMID 37652067

2

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

enthalten in: Science translational medicine | 2023

von Widge, A. | Hofstetter, A. | Houser, K. | +123

3

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA : a first-in-human, phase 1, open-label, dose-escalation trial

enthalten in: Lancet (London, England) | 2023

von Hamer, M. | Houser, K. | Hofstetter, A. | +53

CommentIn: Lancet. 2023 Jan 28;401(10373):251-253. - PMID 36709065

4

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

enthalten in: bioRxiv.org | 2022

von Pegu, A. | O’Connell, S. | Schmidt, S. | +28

5

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

enthalten in: The New England journal of medicine | 2022

von Wu, R. | Idris, A. | Berkowitz, N. | +127

CommentIn: N Engl J Med. 2022 Aug 4;387(5):460-461. - PMID 35921456

6

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV : a phase 1, dose-escalation trial

enthalten in: Nature medicine | 2022

von Casazza, J. | Cale, E. | Narpala, S. | +85

7

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent Vaccines

enthalten in: ResearchSquare.com | 2022

von Anderson, E. | Jackson, L. | Rouphael, N. | +34

8

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults : A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

enthalten in: EClinicalMedicine | 2022

von Houser, K. | Gaudinski, M. | Happe, M. | +43

9

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants

enthalten in: bioRxiv.org | 2021

von Wang, L. | Zhou, T. | Zhang, Y. | +44

10

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

enthalten in: Science (New York, N.Y.) | 2021

von Pegu, A. | O'Connell, S. | Schmidt, S. | +98

UpdateOf: bioRxiv. 2021 May 16;:. - PMID 34031659